Natco Pharma to host Q3FY26 Earnings Call on Feb 12, 2026
Natco Pharma will hold an earnings call on February 12, 2026, at 4 PM IST to discuss Q3FY26 results. Vice-chairman Rajeev Nannapaneni and EVP Rajesh Chebiyam will participate. The call is organized by Batlivala & Karani Securities.
This is a routine announcement about a conference call to discuss financial results. It does not contain new material financial information or strategic decisions that would significantly impact the company's stock price.
The announcement is a routine disclosure about an upcoming earnings call and does not contain any financial results or forward-looking statements that would indicate a positive or negative sentiment.
Natco Pharma Limited has announced its upcoming Earnings Call to discuss the Un-audited Financial Results for the quarter and nine months ended December 31, 2025. The call is scheduled for Thursday, February 12, 2026, at 16:00 PM IST.
Mr. Rajeev Nannapaneni, Vice-chairman and CEO, and Mr. Rajesh Chebiyam, Executive Vice President - Crop Health Sciences, will represent Natco Pharma during the call. The event is being organized in conjunction with India Equity Research, hosted by Batlivala & Karani Securities India Pvt. Ltd.
Investors and analysts can join the call using the provided dial-in numbers. A link for Diamond Pass registration has also been shared for express joining. The company has submitted a copy of the announcement to the BSE Limited and the National Stock Exchange of India Ltd.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.